NCT07353333Not yet recruitingNot Applicable
Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology0 sites6 target enrollmentStarted: January 30, 2026Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 6
Study Overview
Brief Summary
This project will target patients with highly clinically suspected or histopathology diagnosed hepatocellular carcinoma (HCC) using targeted GPC3-specific imaging agents (e.g. , Iodine-131-aGPC3-Scfv) for integrated SPECTCT imaging, to evaluate the pharmacokinetics distribution of the targeted drug in patients with hepatocellular carcinoma (HCC) by low-dose integrated diagnosis and treatment (i.e. , Iodine-131-RRB- imaging, to determine the metabolism, safety and tolerability of the drug in vivo Secondary objective: to evaluate the targeting of GPC3-SPECIFIC imaging agents in patients with hepatocellular carcinoma to assess the feasibility of this targeted agent for future treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •the subject or his/her legal representative can sign and date the informed consent form
- •commitment to follow the research procedures and cooperate in the implementation of the full-process research
- •patients with high clinical suspicion or histopathology diagnosis of HCC and generally in good condition
- •patients with a history of hepatocellular carcinoma who recur after treatment
- •women in their reproductive years were using contraception for at least one month before screening and were committed to using contraception throughout the study period and for the prescribed period after the end of the study
Exclusion Criteria
- •inability to complete SPECTCT examination (including inability to lie down, claustrophobia, radiophobia, etc.)
- •acute systemic diseases and electrolyte disorders
- •patients with known hypersensitivity to GPC3 imaging agents or synthetic excipients
- •patients considered by the investigator to have poor adherence
- •pregnant or lactating patients
- •Have other factors not suitable to participate in this test
Investigators
Similar Trials
Recruiting
Not Applicable
New Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma NodulesHepatocellular CarcinomaNCT07272083Fondazione Policlinico Universitario Agostino Gemelli IRCCS200
Recruiting
Phase 2
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaNCT07328009Fudan University350
Enrolling By Invitation
Not Applicable
STOP HCC-GAAD-APAC-ThailandCirrhosisNCT07319299Mahidol University2,100
Not yet recruiting
Phase 1/2
CHOPIN2024-516127-14-01Leids Universitair Medisch Centrum (LUMC)88
Recruiting
Phase 2
F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of SurvivalHepatocellular carcinoma2023-508709-26-00Universitair Ziekenhuis Gent32